COVID-19: The Ethno-Geographic Perspective of Differential Immunity

Author:

Abdullah Usman1,Saleh Ned2,Shaw Peter3ORCID,Jalal Nasir13

Affiliation:

1. Department of Biomedical Sciences, Pak-Austria Fachhochschule, Mang, Haripur 22621, Pakistan

2. Synsal Inc., San Jose, CA 95138, USA

3. Oujiang Lab, Zhejiang Lab for Regenerative Medicine, Vision and Brain Health, Wenzhou 325000, China

Abstract

Coronavirus disease 2019 (COVID-19), the agent behind the worst global pandemic of the 21st century (COVID-19), is primarily a respiratory-disease-causing virus called SARS-CoV-2 that is responsible for millions of new cases (incidence) and deaths (mortalities) worldwide. Many factors have played a role in the differential morbidity and mortality experienced by nations and ethnicities against SARS-CoV-2, such as the quality of primary medical health facilities or enabling economies. At the same time, the most important variable, i.e., the subsequent ability of individuals to be immunologically sensitive or resistant to the infection, has not been properly discussed before. Despite having excellent medical facilities, an astounding issue arose when some developed countries experienced higher morbidity and mortality compared with their relatively underdeveloped counterparts. Hence, this investigative review attempts to analyze the issue from an angle of previously undiscussed genetic, epigenetic, and molecular immune resistance mechanisms in correlation with the pathophysiology of SARS-CoV-2 and varied ethnicity-based immunological responses against it. The biological factors discussed here include the overall landscape of human microbiota, endogenous retroviral genes spliced into the human genome, and copy number variation, and how they could modulate the innate and adaptive immune systems that put a certain ethnic genetic architecture at a higher risk of SARS-CoV-2 infection than others. Considering an array of these factors in their entirety may help explain the geographic disparity of disease incidence, severity, and subsequent mortality associated with the disease while at the same time encouraging scientists to design new experimental approaches to investigation.

Funder

Oujiang lab

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference88 articles.

1. (2022, March 19). Coronavirus Disease (COVID-19)—World Health Organization. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.

2. The Architecture of SARS-CoV-2 Transcriptome;Kim;Cell,2020

3. COVID-19 Pathophysiology: A Review;Yuki;Clin. Immunol.,2020

4. Shoaib, N., Noureen, N., Munir, R., Shah, F.A., Ishtiaq, N., Jamil, N., Batool, R., Khalid, M., Khan, I., and Iqbal, N. (2021). COVID-19 Severity: Studying the Clinical and Demographic Risk Factors for Adverse Outcomes. PLoS ONE, 16.

5. (2022, March 20). Is the Severe COVID-19 Over in Europe?. Available online: https://healthmanagement.org/c/icu/issuearticle/is-the-severe-covid-19-over-in-europe.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3